Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Rallybio Corporaton (RLYB)

Rallybio Corporaton (RLYB)
0.7200 -0.0100 (-1.37%) 13:57 ET [NASDAQ]
0.7004 x 4 0.7417 x 129
Realtime by (Cboe BZX)
0.7004 x 4 0.7417 x 129
Realtime - - (-) -
Quote Overview for Thu, Mar 20th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.7000
Day High
0.7300
Open 0.7100
Previous Close 0.7300 0.7300
Volume 13,384 13,384
Avg Vol 42,309 42,309
Stochastic %K 62.11% 62.11%
Weighted Alpha -62.22 -62.22
5-Day Change +0.0443 (+6.75%) +0.0443 (+6.75%)
52-Week Range 0.6200 - 3.4600 0.6200 - 3.4600
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,335
  • Shares Outstanding, K 41,612
  • Annual Sales, $ 640 K
  • Annual Income, $ -57,780 K
  • EBIT $ -61 M
  • EBITDA $ -62 M
  • 60-Month Beta -1.45
  • Price/Sales 48.05
  • Price/Cash Flow N/A
  • Price/Book 0.49
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.10
  • Most Recent Earnings $-0.25 on 03/13/25
  • Next Earnings Date 05/08/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.26
  • Number of Estimates 2
  • High Estimate -0.21
  • Low Estimate -0.31
  • Prior Year -0.47
  • Growth Rate Est. (year over year) +44.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6200 +12.95%
on 03/13/25
Period Open: 0.7701
0.8288 -15.50%
on 02/21/25
-0.0698 (-9.06%)
since 02/20/25
3-Month
0.6200 +12.95%
on 03/13/25
Period Open: 0.9500
1.0799 -35.15%
on 01/06/25
-0.2497 (-26.28%)
since 12/20/24
52-Week
0.6200 +12.95%
on 03/13/25
Period Open: 1.6800
3.4600 -79.76%
on 04/11/24
-0.9797 (-58.32%)
since 03/20/24

Most Recent Stories

More News
Stock Index Futures are Higher after Wholesale Prices Increased Less Than Expected in March

June S&P 500 E-Mini futures (ESM24) are up 0.02%, and June Nasdaq 100 E-Mini futures (NQM24) are up 0.17%% this morning, after the release of the PPI data.

ESM24 : 5,471.89s (-0.09%)
NQM24 : 19,747.29s (-0.08%)
DECK : 116.95 (-1.76%)
MCHP : 51.80 (-5.08%)
ADI : 205.43 (-2.16%)
MNDY : 264.89 (+0.84%)
NVDA : 118.82 (+1.11%)
JPM : 239.56 (+0.19%)
WFC : 72.58 (-0.25%)
C : 72.22 (+1.09%)
GLE.FP : 42.300 (-1.33%)
RLYB : 0.7211 (-1.08%)
Rallybio to Present at the JMP Securities 2023 Life Sciences Conference

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,...

RLYB : 0.7211 (-1.08%)
Rallybio Announces Clinical Proof-of-Concept Results for RLYB211, an Anti-HPA-1a Polyclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and Haemostasis

Rallybio Corporation (Nasdaq: RLYB) today announced publication of Phase 1 / 2 proof-of-concept results for RLYB211, a polyclonal anti-HPA-1a antibody derived from human plasma for the prevention of FNAIT....

RLYB : 0.7211 (-1.08%)
Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)

Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for RLYB212 reporting results from the Phase 1b proof-of-concept study has been accepted for presentation at the 31 st Congress of...

RLYB : 0.7211 (-1.08%)
Rallybio Reports Fourth Quarter and Full Year 2022 Financial Results

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,...

RLYB : 0.7211 (-1.08%)
Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia

Rallybio Corporation (Nasdaq: RLYB) today announced that clinical proof-of-concept has been achieved in a Phase 1b study for RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and...

RLYB : 0.7211 (-1.08%)
Rallybio to Present at Upcoming Investor Conferences in March

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,...

RLYB : 0.7211 (-1.08%)
EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy

EyePoint Pharmaceuticals, Inc., a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, and Rallybio Corporation (NASDAQ: RLYB),...

RLYB : 0.7211 (-1.08%)
EYPT : 6.06 (-2.10%)
Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial Officer

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,...

RLYB : 0.7211 (-1.08%)
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2023

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,...

RLYB : 0.7211 (-1.08%)

Business Summary

Rallybio Corporation is a clinical-stage biotechnology company committed to identifying and accelerating the development of therapies for patients with severe and rare diseases. Rallybio Corporation is headquartered in New Haven, Connecticut.

See More

Key Turning Points

3rd Resistance Point 0.8360
2nd Resistance Point 0.8030
1st Resistance Point 0.7660
Last Price 0.7211
1st Support Level 0.6960
2nd Support Level 0.6630
3rd Support Level 0.6260

See More

52-Week High 3.4600
Fibonacci 61.8% 2.3751
Fibonacci 50% 2.0400
Fibonacci 38.2% 1.7049
Last Price 0.7211
52-Week Low 0.6200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals